Browse diseases

…d in the clinic to markedly enhance adoptive T cell therapy for solid tumors.Acknowledgments C.H.P., I.S., Y.L., M.N.P., and J.D.P. are empl…

…geting with CAR T cell immunotherapies for durable remission of solid tumors.Reference Kalia V, Penny LA, Yuzefpolskiy Y, Baumann FM, Sarkar…

…se I trial data demonstrates clinical activity in patients with solid tumors, with a number of durable responses. This data supports the pot…

…py to enhance and restore response to immunotherapy in advanced solid tumors.Trial Registration Clinically, our study includes patients recr…

…rful platform for next-generation personalized immunotherapy in solid tumors. By capturing a wide mutational spectrum—including exon-transpo…

…i A, Ahmadi M, Logue S, Orive G, Pecic S, Gordon JW, Ghavami S. Rhabdomyosarcoma: current therapy, challenges, and future approaches to treatmen…

…s, will improve CAR T cell persistence and anti-tumor effect in solid tumors.Methods We developed Synthetic Gene Expression Regulatory Switc…

…gical malignancies like B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, the application of BiTEs in solid tumors has proven c…

…ty, offering a novel strategy to expand CAR-Mφ applications for solid tumors.…

…d as alternative approaches, showing early signs of activity in solid tumors. Despite these advances, single-lineage ex vivo CAR approaches …

…n patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: preliminary results of the randomized phase II TACITO trial. A…

…ng osteosarcoma (143B, SAOS2), rhabdomyosarcoma (RD, Rh30), and Ewing Sarcoma (TC71), were evaluated by ELISA for TGFB cytokine secretion. We…